22nd week of 2013 patent applcation highlights part 46 |
Patent application number | Title | Published |
20130137626 | MICROCAPSULES AND PRODUCTION THEREOF - The invention relates to microcapsules, the capsule walls of which comprise a resin that can be obtained by reacting a) at least one compound selected from the group consisting of a1) amines and a2) aromatic or heteroaromatic compounds which are unsubstituted or substituted with one or more substituents from the group consisting of C | 2013-05-30 |
20130137627 | METHODS AND KITS FOR IDENTIFYING A PREMATURE INFANT AT RISK OF HAVING OR DEVELOPING BRONCHOPULMONARY DYSPLASIA - The invention relates to methods and kits of identifying a premature infant at risk of having or developing bronchopulmonary dysplasia. More particularly, the present invention relates to a method of identifying a premature infant having or at risk of developing bronchopulmonary dysplasia, said method comprising detecting in a sample obtained from said premature infant at least one polymorphism in the SPOCK2 gene and/or its associated promoter, wherein the presence of said polymorphism indicates an increased risk of having or developing bronchopulmonary dysplasia. | 2013-05-30 |
20130137628 | Dimeric Oxidation-Resistant Apolipoprotein A1 Variants - An isolated oxidation-resistant ApoA1 variant dimer includes a first oxidation-resistant ApoA1 variant polypeptide monomer and a second oxidation-resistant ApoA1 variant polypeptide monomer, wherein at least one of the first and the second monomers comprises at least one amino acid substitution of a tryptophan residue for an oxidation resistant amino acid, or a functional fragment or variant thereof. Methods for treating a disease or disorder comprises administering to a subject in need thereof, a therapeutically effective amount of an isolated oxidation-resistant ApoA1 variant dimer, an oxidation-resistant ApoA1 variant monomer, an oxidation-resistant ApoA1 monomer-lipid complex, a lipid complexed oxidation-resistant ApoA1 variant monomer, a lipid complexed oxidation-resistant ApoA1 variant dimer, or combinations thereof to the subject to enhance cholesterol efflux activity in the presence of an oxidant. | 2013-05-30 |
20130137629 | COMBINATION TREATMENT FOR METABOLIC DISORDERS - Various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis can be treated with a compound selected from an incretin mimetic and a dipeptidyl peptidase IV inhibitor in combination with a Compound of Formula I or a pharmaceutically acceptable salt thereof | 2013-05-30 |
20130137630 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS - Described is a A liquid colloidal pharmaceutical formulation of a type B lantibiotic for infusion or direct injection comprising a type B lantibiotic or a salt thereof, an isotonic aqueous solution comprising a sugar alcohol such as glycerol and/or a saccharide and optionally a buffer, wherein said final formulation for infusion or direct injection is clear of visual particulates. | 2013-05-30 |
20130137631 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES - The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 2013-05-30 |
20130137632 | Method of Treating a Subject According to Biomarkers for Insulin Resistance - The invention provides compositions and methods for determining insulin resistance and/or pancreatic β-cell dysfunction in a subject. The invention also provides compositions and methods for treating a subject according to the insulin resistance and/or pancreatic β-cell dysfunction in the subject. | 2013-05-30 |
20130137633 | mTOR KINASE-ASSOCIATED PROTEINS - The invention describes isolated mTOR-associated proteins (“mTOR-APs”) as well as isolated variants and fragments thereof and the isolated nucleic acids encoding them. The invention also describes vectors and host cells containing nucleic acid encoding an mTOR-AP polypeptide and methods for producing an mTOR-AP polypeptide. Also described are methods for screening for compounds which modulate mTOR-AP activity and methods for treating or preventing a disorder that is responsive to mTOR-AP modulation. | 2013-05-30 |
20130137634 | COMPOUNDS AND COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO - The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a compound disclosed herein, such as 2,4-diamino-1,3,5-triazine derivatives or salts thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement. | 2013-05-30 |
20130137635 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE - This invention relates to tryptophan hydroxylase inhibitors, compositions comprising them, and methods of their use for the treatment, management and/or prevention of metastatic bone disease. | 2013-05-30 |
20130137636 | RECOMBINANT HUMAN FOLLICLE-STIMULATING HORMONE - The present invention pertains to improved FSH preparations which are capable of stimulating sex steroid release at much lower concentration than the commonly used urinary FSH or recombinant FSH obtained from CHO cells and which act independent of cAMP signaling These improved FSH preparations can be used in infertility treatment. | 2013-05-30 |
20130137637 | PEPTIDES FOR PROMOTING ANGIOGENESIS AND AN USE THEREOF - The present invention relates to a peptide promoting angiogenesis and novel use thereof. More particularly, the invention relates to peptides promoting angiogenesis, and the use of the peptide for promoting angiogenesis and preventing or treating angiogenesis-related disease. The peptide of the present invention have an excellent effect on promoting angiogenesis. Accordingly, it is useful for preventing or treating angiogenesis-related disease and for preparing regeneration of skin flap, wound and burn healing, implantation of artificial skin and preparation of blood vessels for transplantation. | 2013-05-30 |
20130137638 | CONJUGATED FACTOR VIII MOLECULES - The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules. | 2013-05-30 |
20130137639 | STABLE MIA/CD-RAP FORMULATION - The present invention relates to stable aqueous formulations comprising at least 5 mg/mL CD-RAP and a charged amino acid, said amino acid preferably having a net charge at a pH between about 6 and 8. The ingredients of the formulation preferably provide stability over repeated freeze-thaw cycles. In a preferred aspect, the formulation is for use in therapy, preferably for use in the treatment of inflammatory disorders, preferably osteoarthritis. Furthermore, a kit comprising the formulation of the invention is provided. | 2013-05-30 |
20130137640 | Skin Collagen Enhancing Agent - A composition includes a food ingredient or nutrient with safety and experience having been eaten for a long time and that shows a collagen enhancing activity. The food ingredient or nutrient of the composition includes a skin collagen enhancing agent that includes menaquinone-7 as an active ingredient. The composition including skin collagen enhancing agent can be administered percutaneously or orally as a drug, a cosmetic, or a supplement. | 2013-05-30 |
20130137641 | METHODS FOR TREATING PAIN - The invention provides agents useful for treating pain. An exemplary agent comprises or consists of the a portion of a retroviral Tat protein. One such agent is the peptide Tat-NR2B9c. This peptide has previously been described as an agent for inhibiting damaging effects of stroke and similar conditions via inhibition of PSD95 interactions with NMDA receptors and/or NOS. The present application provides data showing that the Tat-NR2B9c peptides is effective in alleviation of pain. The alleviation of pain can be obtained at a dose of the peptide below the dose required to inhibit PSD-95 interactions with NMDAR or NOS. | 2013-05-30 |
20130137642 | METHODS AND COMPOSITIONS FOR PRESERVING PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIAL CELLS - Provided are methods and compositions for maintaining the viability of photoreceptor cells and/or retinal pigment epithelial cells in a subject with an ocular disorder including, for example, age-related macular degeneration (AMD) (e.g., dry or neovascular AMD), retinitis pigmentosa (RP), or a retinal detachment. The viability of the photoreceptor cells and/or the retinal pigment epithelial cells can be preserved by administering a necrosis inhibitor either alone or in combination with an apoptosis inhibitor to a subject having an eye with the ocular condition. The compositions, when administered, maintain the viability of the cells, thereby minimizing the loss of vision or visual function associated with the ocular disorder. | 2013-05-30 |
20130137643 | MATERNAL SIALIC ACID SUPPLEMENTATION - The invention provides methods and compositions for improving fetal and child health and development through nutritional supplementation with, for example, sialic acid. Sialic acid can be provided to a female before, during and/or after pregnancy to improve the health and development of a fetus and/or child. The sialic acid can be in a variety of forms in the supplements. | 2013-05-30 |
20130137644 | CELL PENETRATING PEPTIDE CONJUGATES FOR DELIVERING OF NUCLEIC ACIDS INTO A CELL - The invention provides cell penetrating peptide-nucleic acid conjugates having the formula P-L-N, wherein P is a cell penetrating peptide, N is a nucleic acid, preferably an oligonucleotide and more preferably a siRNA, and L is a hydrophilic polymer, preferably a polyethylene glycol (PEG)-based linker linking P and N together. Compositions, methods of use and methods for producing such conjugates are also disclosed. | 2013-05-30 |
20130137645 | MODIFIED PEPTIDES AND PROTEINS - Provided are compounds and methods of making compounds containing two or three groups derived from a peptide, such as enfuvirtide or exenatide, covalently bound to a linker. The compounds may contain polyethylene glycol groups to enhance solubility and pharmacokinetic properties. The compounds are useful for the treatment of diseases or conditions subject to treatment with the parent peptide, such as HIV and AIDS in the case of enfuvirtide, or diabetes in the case of exenatide. | 2013-05-30 |
20130137646 | METHODS OF TREATMENT, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - The invention relates to methods for preventing, slowing the progression of, delaying or treating metabolic disorders induced in patients by the treatment with neuroleptic agents comprising administering to the patients an SGLT2 inhibitor. | 2013-05-30 |
20130137647 | NATURAL MEDICINAL COMPOUND - This invention refers to the sector of drugs intended for both human and animal use, and it particularly concerns a natural medicinal compound that contains a tannin-based vegetal active ingredient combined with carriers and with a synergic effect, wherein the vegetal active ingredient is natural chestnut extract ( | 2013-05-30 |
20130137648 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS - Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme. | 2013-05-30 |
20130137649 | EPIGENETIC MECHANISMS OF ANTI-FIBROTIC ACTION FOR THE LIVER - This invention demonstrates the therapeutic efficacy of Yang-Gan-Wan (YGW) and its active components, especially in the formulation provided by Sheng-Pu Pharmaceutials, Inc., for treating and preventing liver fibrosis. This invention further demonstrates MeCP2 is an important therapeutic target for YGW and its active ingredients' action against liver fibrosis and cirrhosis. | 2013-05-30 |
20130137650 | METHODS OF TREATMENT USING COMBINATION THERAPY - Provided herein are methods of treating a proliferative disease in a subject, comprising administering to the subject a therapeutically effective amount of AC220 and a nucleoside analog, a topoisomerase inhibitor or an anthracycline, or a combination thereof. | 2013-05-30 |
20130137651 | GEL USEFUL FOR THE DELIVERY OF OPHTHALMIC DRUGS - The present invention relates to a solid powder composed of a mixture of a natural or a synthetic polymer which forms a gel, a buffer, such as an hydroxyacid or a dicarboxyacid, a saccharide, one or more drugs useful for the treatment of diseases of the eyes and optionally one or more excipients and/or regulators of the osmotic pressure ophthalmologically acceptable. | 2013-05-30 |
20130137652 | COMBINATION OF A PYRROLOQUINOLINE COMPOUND AND AN AMINOGLYCODISE ANTIMICROBIAL AGENT - This invention relates to the use of 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable derivative thereof in combination with an aminoglycoside antimicrobial agent for the prevention and/or treatment of microbial infections. | 2013-05-30 |
20130137653 | THEANINE DERIVATIVE, PREPARATION METHOD THEREOF, AND USE THEREOF FOR ALLEVIATING ACNE - The present invention relates to a theanine derivative, a preparation method thereof, and a use thereof for anti-acne treatment, having a selective inhibitory effect on | 2013-05-30 |
20130137654 | NUCLEOSIDE PHOSPHORAMIDATES - Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals. | 2013-05-30 |
20130137655 | Cytochrome P450 Enzyme Complexes And Methods Of Treatment Using The Same - The present invention provides methods and compositions for balancing electron reduction potentials of formulations in a manner that reduces susceptibility to changes from xenobiotics. The present invention also provides novel compositions of matter based on structuring from a mobile nucleotide integral to its architecture. | 2013-05-30 |
20130137656 | PHARMACEUTICAL/ COSMETIC COMPOSITION COMPRISING HYALURONIC ACID AND TREATMENT OF DERMATOLOGICAL CONDITIONS THEREWITH - Pharmaceutical/cosmetic compositions containing a dermatologically effective amount of hyaluronic acid, at least one retinoid and/or salt and/or derivative thereof, at least one oligosaccharide and at least one inhibitor of hyaluronic acid degradation, formulated into a physiologically acceptable medium therefor, are useful for the treatment of wrinkles, fine lines, fibroblast depletions and scars. | 2013-05-30 |
20130137657 | QUATERNISED AMMONIUM CYCLODEXTRIN COMPOUNDS - Use of a compound of formula (I): | 2013-05-30 |
20130137658 | PLANT DISEASE CONTROLLING COMPOSITION AND USE THEREOF - A plant disease controlling composition is provided containing a pyridazine compound represented by formula (I): | 2013-05-30 |
20130137659 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - Provided herein are compounds of formula (I): | 2013-05-30 |
20130137660 | INHIBITORS OF KINASE ACTIVITY - The present invention relates to pyridines or pyrazines that inhibit kinases. In particular the compounds of the invention inhibit members of the class III PTK receptor family such as FMS (CSF-IR), c-KIT, PDGFRβ, PDGFRα or FLT3 and KDR, SRC, EphA2, EphA3, EphA8, FLT1, FLT4, HCK, LCK, PTK5 (FRK), SYK, DDR1 and DDR2 and RET. The compounds of the invention are useful in the treatment of kinase associated diseases such as immunological and inflammatory diseases; hyperproliferative diseases including cancer and diseases involving neo-angiogenesis; renal and kidney diseases; bone remodeling diseases; metabolic diseases; and vascular diseases. | 2013-05-30 |
20130137661 | Gonadotropin Releasing Hormone Receptor Antagonist, Preparation Method Thereof And Pharmaceutical Composition Comprising The Same - Disclosed are compounds useful as gonadotrophin-releasing hormone (“GnRH”) receptor antagonist. | 2013-05-30 |
20130137662 | USE OF CANTHAXANTHIN AND/OR 25-OH D3 FOR IMPROVED REPRODUCTIVITY AND PERFORMANCE OF ROOSTERS - The present invention relates to the use canthaxanthin and/or 25-hydroxy vitamin D3 (25-OH D3) for improving reproductive performance of roosters. More particularly, the invention relates to the use of Canthaxanthin and/or 25-hydroxy canthaxanthin in the manufacture of a food or veterinary composition for improving reproductive performance of roosters. | 2013-05-30 |
20130137663 | METHODS AND COMPOSITIONS FOR REDUCING PARATHYROID LEVELS - Methods and compositions for reducing serum parathyroid levels in, for example, chronic kidney disease patients are disclosed. In these methods, an effective amount of a modified release formulation of 25-hydroxy vitamin D is orally administered to a patient suffering from secondary hyperparathyroidism to lower the patient's serum intact parathyroid hormone (iPTH) level, while avoiding a surge in serum total 25-hydroxy vitamin D. | 2013-05-30 |
20130137664 | LOW-DOSED SOLID ORAL DOSAGE FORMS FOR HRT - The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP doses it has surprisingly been found that a high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated. | 2013-05-30 |
20130137665 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY - This invention relates to a compound of formula I: | 2013-05-30 |
20130137667 | LIGANDS FOR NEMATODE NUCLEAR RECEPTORS AND USES THEREOF - An effective anti-nematode methodology entails contacting nematodes with a biologically effective amount of at least one compound according to formula I: | 2013-05-30 |
20130137668 | Antimicrobial Cationic Steroids and Methods of Use - The invention relates generally to antimicrobial cationic steroid pharmaceutical compositions, methods of making antimicrobial cationic steroid pharmaceutical compositions, and methods of using antimicrobial cationic steroid pharmaceutical compositions. | 2013-05-30 |
20130137669 | MACROCYCLIC LACTONE RESISTANCE MARKER FOR DIROFILARIA IMMITIS - The invention relates to a method for determining the responsiveness of a | 2013-05-30 |
20130137670 | ZWITTERION SOLUTION FOR LOW-VOLUME THERAPEUTIC DELIVERY - A formulation is provided that includes a volume of an aqueous multivalent physiological ion solution compatible with cerebrospinal fluid containing at least one divalent cation of magnesium or calcium, and at least one anion of carbonate or phosphate, and having a pH between 6.5 and 8.0. A zwitterionic therapeutic agent other than baclofen is dissolved the solution to achieve higher concentration or ease of solution and/or storage relative to therapeutic saline solutions of the same agent. A process of delivering a zwitterionic therapeutic agent into a subject is provided that includes dissolving a therapeutic amount of the zwitterionic therapeutic agent in a volume of artificial cerebrospinal fluid to form a stable formulation. The solution is then administered to the subject using an intrathecal pump. | 2013-05-30 |
20130137671 | Substituted Triazole Derivatives As Oxytocin Antagonists - The present invention relates to substituted triazoles of formula (I), uses thereof, processes for the preparation thereof and compositions containing said compounds. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction. | 2013-05-30 |
20130137672 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS - Certain disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo[3.2.0]heptane are described, which are useful as orexin inhibitors. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia. | 2013-05-30 |
20130137673 | INHIBITORS OF JAK - The present invention is directed to compounds of formula I and tautomers and pharmaceutically acceptable salts thereof which are selective inhibitors of JAK. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK activity, and methods to prevent or treat a number of conditions mediated at least in part by JAK activity. | 2013-05-30 |
20130137674 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS - Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: | 2013-05-30 |
20130137675 | HETEROCYCLIC COMPOUND AND USE THEREOF - The present invention aims to provide a compound having a PDE inhibitory action and useful as a medicament for the prophylaxis or treatment of schizophrenia and the like. | 2013-05-30 |
20130137676 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES - The invention relates to a compound of formula (I) | 2013-05-30 |
20130137677 | Bicyclic Azaheterocyclic Carboxamides - The invention provides novel bicyclic azaheterocyclic carboxamide compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer. | 2013-05-30 |
20130137678 | Antiviral Compounds and Uses Thereof - Described herein are Compounds, compositions comprising such Compounds, and the use of such Compounds and compositions as anti-viral agents. In one aspect, provided herein are methods of inhibiting viral replication using Compounds described herein or compositions thereof. In another aspect, provided herein are methods for preventing a symptom of a viral infection using a Compound, or a composition thereof. In another aspect, provided herein are methods of treating and/or managing viral infection using a compound or a composition thereof. | 2013-05-30 |
20130137679 | Novel Functionally Selective Ligands of Dopamine D2 Receptors - The present invention relates to novel functionally selective ligands of dopamine D2 receptors, FIG. | 2013-05-30 |
20130137680 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE - The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salt thereof, wherein R | 2013-05-30 |
20130137681 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS - The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases. | 2013-05-30 |
20130137682 | PEST CONTROL COMPOSITION - A pest control composition comprising a hydrazide compound shown by formula (1) below (in the formula, G, M, Q | 2013-05-30 |
20130137683 | PLANT DISEASE CONTROLLING COMPOSITION AND USE THEREOF - A plant disease controlling composition containing a pyridazine compound represented by formula (I): | 2013-05-30 |
20130137684 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS - The present invention generally relates to compounds that inhibit haematopoietic-prostaglandin D | 2013-05-30 |
20130137685 | 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES - The invention relates to oxazolopyrimidine compounds of formula (I), where A, R | 2013-05-30 |
20130137686 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES - Disclosed are compounds and pharmaceutically acceptable salts of Formula I | 2013-05-30 |
20130137687 | NOVEL PYRROLIDINE DERIVATIVES - The invention relates to a compound of formula (I) | 2013-05-30 |
20130137688 | NOVEL COMPOUNDS - This invention relates to compounds of formula I | 2013-05-30 |
20130137689 | NOVEL ACYLPIPERAZINONES AND THEIR USE AS PHARMACEUTICALS - The invention relates to novel acylpiperazinone compounds, to the preparation of the compounds and intermediates used therein, to the use of the compounds as antibacterial medicaments and pharmaceutical compositions containing the compounds. | 2013-05-30 |
20130137690 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS - The present invention relates to a novel class of 4-carboxybenzylamino derivatives. The 4-carboxybenzylamino compounds can be used to treat cancer. The 4-carboxybenzylamino compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the 4-carboxybenzylamino derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the 4-carboxybenzylamino derivatives in vivo. | 2013-05-30 |
20130137691 | DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS - The invention relates to compounds of formula (I): | 2013-05-30 |
20130137692 | PLANT DISEASE CONTROLLING COMPOSITION AND USE THEREOF - A plant disease controlling composition containing a pyridazine compound represented by formula (I): | 2013-05-30 |
20130137693 | LISOFYLLINE ANALOGS AND METHODS FOR USE - Analogs of a Lisofylline (LSF), and synthetic methods for the preparation of such analogs are provided. The analogs of LSF provided have the ability to protect cell viability, particularly the ability to protect pancreatic β-cells. | 2013-05-30 |
20130137694 | NOVEL MODULATORS OF NRF2 AND USES THEREOF - There is provided modulators of Nrf2 protein which comprises a compound which binds at least one of the BTB domain, IVR domain and Kelch domain of Keap1 protein, activating or inhibiting Nrf2. There is also provided pharmaceutical compositions containing the modulators, as well as uses and method of use of the modulators for the treatment of conditions. | 2013-05-30 |
20130137695 | SUBSTITUTED 4-(4-FLUORO-3-(PIPERAZINE-1-CARBONYL)BENZYL)PHTHALAZIN-1(2H)-ONE DERIVATIVES AS POLY (ADP-RIBOSE) POLYMERASE-1 INHIBITORS - Disclosed are compounds of general formula (I), their stereoisomers, regioisomers, tautomeric forms and novel intermediates involved in their synthesis, their pharmaceutically acceptable salts. These compounds are suitable as Poly (ADP-ribose) polymerase-1 inhibitors (PARP-1 inhibitors). | 2013-05-30 |
20130137696 | 3,4-DIHYDRO-2H-PYRROLO[1,2-A]PYRAZIN-1-ONE DERIVATIVES FOR THE MODULATION OF THE ACTIVITY OF PROTEIN KINASES - Compounds which are 4,7-disubstituted derivatives of 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one compounds, or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, viral infection, prevention of AIDS development in HIV-infected individuals, cell proliferative disorders, autoimmune and neurodegenerative disorders; also disclosed is a process under Solid Phase Synthesis conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them. | 2013-05-30 |
20130137697 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT - Briefly described, embodiments of this disclosure, among others, include compositions, pharmaceutical compositions, methods of treating nicotine dependence, methods of treating a subject who smokes and has a risk for depression or other neuropsychiatric disorder, method of treating a subject who smokes and has a risk for depression or other neuropsychiatric disorders, and the like. | 2013-05-30 |
20130137698 | SOLID ORAL FILM DOSAGE FORMS AND METHODS FOR MAKING SAME - Improved pharmaceutical solid oral film dosage forms for the buccal and/or sublingual delivery of pharmaceutical, nutraceutical or cosmetic ingredients are endowed with instant hydration potential and complete dissolution potentially enabling the active ingredient to become immediately available for enhanced buccal and/or sublingual absorption and/or reduced absorption through the gastrointestinal route. The improved delivery systems for solubilizing and stabilizing pharmaceutically active ingredients exhibit enhanced stability by the use of a combination of crystallization inhibitors, which together can maintain the active ingredient in a desired plurality of particles in an effective size range within a polymeric film matrix. | 2013-05-30 |
20130137699 | THERAPEUTIC COMPOUNDS - The invention provides compounds of formula I or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for inducing apoptosis or treating cancer using compounds of formula I. | 2013-05-30 |
20130137700 | FUSED HETEROCYCLIC RING COMPOUND - Provided is a compound having a PDE10A inhibitory action, and useful as a medicament for the prophylaxis or treatment of mental diseases such as schizophrenia and the like, and the like. A compound represented by the formula (I): | 2013-05-30 |
20130137701 | COMBINATION - The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine, or a pharmaceutically acceptable hydrate and/or salt thereof, and 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide, or a pharmaceutically acceptable salt thereof, to a human in need thereof. | 2013-05-30 |
20130137702 | ANTICOAGULANT REVERSAL AGENTS - Novel anticoagulant reversal compounds are disclosed, as well as methods of making the compounds, pharmaceutical compositions including the compounds, methods of using the compounds to reverse the anticoagulant effects of coagulation inhibitors, and diagnostic assays comprising the compounds. | 2013-05-30 |
20130137703 | AMINOPYRIDINE KINASE INHIBITORS - The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. | 2013-05-30 |
20130137704 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS - The present invention relates to novel compounds of Formula (I), wherein X | 2013-05-30 |
20130137705 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE - This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[3,4-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 2013-05-30 |
20130137706 | Antimicrobial Molecules For Treating Multi-Drug Resistant and Extensively Drug Resistant Strains Of Mycobacterium - The present invention provides methods of inhibiting the growth of | 2013-05-30 |
20130137707 | PYRAZOLOPYRIMIDINE PDE 10 INHIBITORS - The present invention is directed to pyrazolopyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction. | 2013-05-30 |
20130137708 | METHODS AND COMPOSITIONS FOR KINASE INHIBITION - The present invention sets forth a new chemical genetic approach for engineering kinase enzymes with a cysteine gatekeeper residue as well as for developing electrophilic inhibitors thereto. The present invention also provides a Src proto-oncogenic tyrosine kinase with a cysteine gatekeeper that recapitulates wild type activity and can be irreversibly inhibited both in vitro and in cells. The present invention also provides methods and compositions for modulating kinases and for treating kinase-associated diseases. | 2013-05-30 |
20130137709 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith - Provided are compounds and methods for treating or preventing kinase-mediated disorders therewith. | 2013-05-30 |
20130137710 | CYCLOHEXYL CARBAMATE COMPOUNDS AS ACTIVE ANTI-CELLULITE INGREDIENTS - The present invention relates to the cosmetic, dermatological or therapeutic use of certain cyclohexyl carbamate compounds of formula (I) given below, preferably as anti-cellulite actives. The invention further relates to compositions and cosmetic, dermatological or therapeutic products comprising such compounds of formula (I), which are preferably suitable for the prophylaxis (prevention) and cosmetic treatment (combating) of cellulite in human beings, corresponding methods and novel compounds of formula (I) | 2013-05-30 |
20130137711 | POLYMORPH FORMS OF 4-ANILINOQUINAZOLINE DERIVATIVES, THE PREPARATION METHODS AND USES THEREOF - The present invention relates to polymorphic forms of N-{4-[3-chloro-4-(3-fluoro-benzyloxy)phenylamino]-quinazolin-6-yl}-acrylamide p-toluenesulfonate with the characteristic X-ray powder diffraction data as stated in the description, preparation methods thereof, pharmaceutical compositions comprising the same and the use thereof. | 2013-05-30 |
20130137712 | Salts of 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-- 3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide - Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide are prepared by various processes. | 2013-05-30 |
20130137713 | METHODS FOR TREATING BOWEL DISEASES - The present invention provides new methods of treating bowel disease (BD) by increasing a durability of response; treating BD in males; treating BD in adolescent subjects; treating bloating due to BD in males; and methods of maintaining remission of BD. | 2013-05-30 |
20130137714 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF DEPRESSION, ANXIETY, AND NEURODEGENERATIVE DISORDERS - Pharmaceutical compositions and methods for treating depression, anxiety, and neurodegenerative diseases and cognitive disorders, such as dementia and Alzheimer's disease, by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine. | 2013-05-30 |
20130137715 | Pharmaceutical Compositions Containing A Fluoroquinolone Antibiotic Drug - Pharmaceutical compositions containing a fluoroquinolone antibiotic drug are disclosed. The compositions exhibit improved homogeneity, improved bioavailability, lower turbidity or a combination thereof. The composition can be use as otic or nasal compositions, but are particularly useful as ophthalmic compositions. | 2013-05-30 |
20130137716 | PARENTERAL DEXTROSE FORMULATION OF CLOPIDOGREL - Described herein are ways to solubilize clopidogrel for parenteral administration containing clopidogrel and D | 2013-05-30 |
20130137717 | Treatment of Cognitive Disorders with (R)-7-Chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-Carboxamide and Pharmaceutically Acceptable Salts Thereof - (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses to improve cognition. | 2013-05-30 |
20130137718 | PROCESS FOR THE PREPARATION OF 2-(CYCLOHEXYLMETHYL)-N--1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE - Industrially applicable process for preparing 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide, and salts thereof. | 2013-05-30 |
20130137719 | Novel 6,7-disubstituted-sioquinoline derivatives and their use - The present invention relates compounds of general formula (I) and stereoisomers and pharmaceutically acceptable salts and prodrugs thereof; wherein R′ and R | 2013-05-30 |
20130137720 | HISTONE DEMETHYLASE INHIBITORS AND METHODS FOR USING THE SAME - The present invention provides compounds, or derivatives or prodrugs thereof, that comprise a methyllysine mimic, and an α-ketoglutarate mimic that are attached through a linker and methods for using and producing the same. In some embodiments, compounds of the invention are of the formula: M-L-K, or a derivative or a prodrug thereof, wherein M is a methyllysine mimic, L is a linker, and K is an α-ketoglutarate mimic. | 2013-05-30 |
20130137721 | 6-AMINOISOQUINOLINE COMPOUNDS - 6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided. | 2013-05-30 |
20130137722 | SOLID FORMS OF N-(4-(7-AZABICYCLO[2.2.1]HEPTAN-7-YL)-2-TRIFLUOROMETHYL)PHENYL)-4-OXO-5-(- TRIFLUOROMETHYL)-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE - The present invention relates to substantially crystalline and solid state forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide (Form A-HCl, Form B, Form B-HCl, or any combination of these forms), pharmaceutical compositions thereof, and methods of treatment therewith. | 2013-05-30 |
20130137723 | CRYSTAL OF ANTI-BACTERIAL COMPOUND - It is intended to provide a salt of a compound and crystals thereof useful as a therapeutic and/or preventive agent for infectious diseases which has wide and excellent antibacterial activity and has excellent safety. | 2013-05-30 |
20130137724 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR RETINAL NEUROPROTECTION - The present invention relates to a method for retinal neuroprotection or for treating retinal diseases, in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 7-(1H-Imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, its enantiomers or pharmaceutically acceptable salts thereof. | 2013-05-30 |
20130137725 | METHOD OF TREATING SENSORIMOTOR DISORDERS WITH ALPHA-2 ADRENERGIC RECEPTOR AGONISTS - Disclosed herein is a method of treating sensorimotor disorders comprising administering to a subject in need of such treatment an alpha-2 receptor agonist lacking significant alpha-2A receptor activity. | 2013-05-30 |
20130137726 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE - Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases. | 2013-05-30 |